Traditional randomized trials are often impractical for treatments in the rare and ultra rare disease space.
Dr. Patricia E. Greenstein
Advertisement
Articles by Dr. Patricia E. Greenstein
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
FDA Approves Idvynso for Treatment of HIV-1 Infection in Adults
2
How is the Role of Non-Viral Cell Engineering Technology Growing in Advanced Therapies?
3
AbbVie Invests $1.4 Billion into New Manufacturing Campus in North Carolina
4
FDA Approves Tzield to Delay Onset of Stage 3 Type 1 Diabetes in Young Children
5